Marshall Wace
Marshall Wace LLP is an employee-owned hedge fund manager based in London, United Kingdom, with additional offices in New York and Hong Kong. Founded in 1997, the firm specializes in global long/short equity investments and manages a variety of hedge funds and equity mutual funds for its clients. Marshall Wace employs a dual approach to asset management, integrating traditional fundamental analysis with proprietary systematic strategies, including its innovative MW TOPS alpha capture strategy. The firm focuses on delivering risk-adjusted returns by investing in public equity markets worldwide, as well as in alternative investment markets. Its diverse investment solutions cater to a range of sectors, including financial services, manufacturing, financial technology, and e-commerce.
SAb Biotherapeutics
Post in 2023
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.